BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32375866)

  • 1. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
    Roderwieser A; Sand F; Walter E; Fischer J; Gecht J; Bartenhagen C; Ackermann S; Otte F; Welte A; Kahlert Y; Lieberz D; Hertwig F; Reinhardt HC; Simon T; Peifer M; Ortmann M; Büttner R; Hero B; O'Sullivan RJ; Berthold F; Fischer M
    JCO Precis Oncol; 2019 Dec; 3():1-20. PubMed ID: 35100718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
    Zheng XH; Nie X; Fang Y; Zhang Z; Xiao Y; Mao Z; Liu H; Ren J; Wang F; Xia L; Huang J; Zhao Y
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
    Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
    Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliable assessment of telomere maintenance mechanisms in neuroblastoma.
    Meeser A; Bartenhagen C; Werr L; Hellmann AM; Kahlert Y; Hemstedt N; Nürnberg P; Altmüller J; Ackermann S; Hero B; Simon T; Peifer M; Fischer M; Rosswog C
    Cell Biosci; 2022 Sep; 12(1):160. PubMed ID: 36153564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.
    Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D
    Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
    J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
    Duan XF; Zhao Q
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
    Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
    J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
    Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
    Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TERT promoter is polycomb-repressed in neuroblastoma cells with long telomeres.
    Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M
    Cancer Res Commun; 2024 May; ():. PubMed ID: 38837897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative lengthening of telomeres does exist in various canine sarcomas.
    Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
    Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
    Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
    Gao J; Pickett HA
    Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.